La Jolla, CA — May 3, 2016 — Synthetic Genomics, Inc. (SGI), a leader in the field of synthetic biology, announced today that Anthony Artuso has joined its executive team as Chief Business Officer. Anthony is an accomplished executive and entrepreneur with over 20 years of broad domestic and international experience in biotech, clean energy, finance, public policy, and sustainable development.
Oliver Fetzer, SGI CEO, said “We are pleased to add Anthony to our executive team and under his leadership we will further expand SGI’s industry leading synthetic biology partnerships. Anthony’s extensive experience in strategy and corporate development will accelerate our commercialization momentum while his breadth and depth of experience make him well suited to play an integral part in SGI’s evolution.”
Before joining SGI, Anthony spent six years with Merck Millipore where he headed the company’s protein and cellular analysis business, and previous to that was in charge of strategic planning and business development for Merck Millipore Bioscience. Anthony’s pharmaceutical industry experience includes building and leading the strategic planning, portfolio management, and competitive intelligence functions at Vertex Pharmaceuticals. Prior to that he spent seven years at Bristol-Myers Squibb, where he was in charge of strategic planning and portfolio management, as well as strategy and decision analysis for new product development, licensing and M&A.
Anthony has also served as a faculty member at the University of Charleston and Rutgers University where he became recognized internationally for his work on the chemical and genetic value of biodiversity. He also advised the World Bank, United Nations, and various U.S. government and multi-national agencies. Earlier in his career, Anthony worked in the public sector where he constructed a blueprint for the deregulation of US electricity generation, directed a billion-dollar capital improvement program and implemented regional water pollution control programs, and served as Chief Financial Officer of a major public sector utility.
About Synthetic Genomics
Synthetic Genomics Inc. (SGI), located in La Jolla, CA, is a leader in the fields of synthetic biology and synthetic genomics, advancing genomics to better life. SGI applies its intellectual property in this rapidly evolving field to design and build biological systems solving global sustainability challenges. SGI serves three end markets: research, bioproduction, and applied products. The company’s research offerings, commercialized through its subsidiary SGI-DNA, are revolutionizing science and medicine with next-generation genomic solutions, including the world’s first DNA printer. SGI applies its integrated synthetic biology capabilities to reinvent bio-based production by improving existing production systems and developing novel, optimized production hosts. SGI develops its applied products, typically in partnership with leading global organizations, across a variety of industries including sustainable bio-fuels, sustainable crops, nutritional supplements, vaccines, and transplantable organs.
Ben Chiarelli, VP of Corporate Development and Strategy